CTOs on the Move

Melinta

www.melinta.com

 
Melinta Therapeutics, Inc. (NASDAQ:MLNT) is the largest pure-play antibiotics company, dedicated to saving lives threatened by the global public health crisis of bacterial infections through the development and commercialization of novel antibiotics that provide new therapeutic solutions. Its four marketed products include Baxdela™ (delafloxacin), Vabomere™ (meropenem and vaborbactam), Orbactiv® (oritavancin), and Minocin® (minocycline) for Injection. It also has an extensive pipeline of preclinical and clinical-stage products representing many important classes of antibiotics, each targeted at a different segment of the anti-infective market. Together, this portfolio provides Melinta with the unique ability to provide providers and patients with a range of ...
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million
  • www.melinta.com
  • 300 George Street Suite 301
    New Haven, CT USA 06511
  • Phone: 203.624.5606

Executives

Name Title Contact Details
Melinta Therapeutics
 Chief Technology Officer Profile

Funding

Melinta raised $67M on 06/10/2015

Similar Companies

Waste Reduction

Waste Reduction is a Indianapolis, IN-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Vivex

Vivex Biomedical, Inc. is a biomaterials developer headquartered in Marietta, Georgia. Vivex is focused on creating treatment options and creative solutions to advance clinical, surgical and therapeutic patient care. We have made significant progress in a short time, bringing together the brightest minds in the scientific community and from the orthopaedic and material science industries. Through our focus on continued innovation in next-generation biomaterials, Vivex is creating a new standard in patient care and delivering groundbreaking health products to meet the needs of a diverse, rapidly expanding market.

Aimmune

Aimmune Therapeutics, Inc. is a biopharmaceutical company that aspires to become the global leader in developing curative therapies and solutions for patients with food allergies. With a mission to improve the lives of people with food allergies, Aimmune is developing and commercializing oral treatments for potentially life-threatening food allergies. The Company`s Characterized Oral Desensitization ImmunoTherapy (CODIT™) approach is intended to provide meaningful levels of protection against allergic reactions resulting from accidental exposure to food allergens by desensitizing patients with defined, precise amounts of key allergens. Aimmune has one FDA-approved medicine for peanut allergy and other investigational therapies in development to treat other food allergies. Aimmune is located in Brisbane, California - the heart of San Francisco`s biotechnology hub - with additional offices in the Kings Cross area of London and in Durham, North Carolina.

Avalyn Pharma

Avalyn is a biopharma company committed to developing improved therapies for the treatment of idiopathic pulmonary fibrosis (IPF) and other severe respiratory diseases. Our lead asset is inhaled pirfenidone (AP01) for the treatment of IPF. With offices in Seattle and San Diego, Avalyn`s experienced clinical and inhaled product development team is rapidly advancing AP01 for the treatment of IPF and additional pipeline candidates for IPF and other severe respiratory diseases.

Protea Biosciences

Protea Biosciences is a Morgantown, WV-based company in the Healthcare, Pharmaceuticals, and Biotech sector.